Structure Therapeutics Inc. (GPCR) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Structure Therapeutics Inc. stock $17.91, price $20.35, that is 12.0% below the price, quality 45 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
45‑month range $14.15 – $93.79 · fair‑value band $11.82 – $22.39 · the $20.35 price screens above the $17.91 fair value. As of Nov 6, 2026.
Follow Structure Therapeutics Inc. American Depositary Shares in your weekly email
Every Wednesday you see whether Structure Therapeutics Inc. American Depositary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Show moreShow less
Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.
In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation.
The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Stock analysis
Structure Therapeutics Inc. (GPCR) currently trades at $20.35, while our model-based Fair Value estimate is $17.91, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $11.82 (bear) to $22.39 (bull), the price of $20.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Structure Therapeutics Inc. American Depositary Shares reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$141M in FY2025.
Key figures
Market cap $1.5B Small · EPS (TTM) $−3.03 · Return on equity −20.2% · Return on assets (EBIT) −28.9% (5-year average) · Free cash flow −$226M · Net cash $793M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 78% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −12%, GPCR screens richer than that median.
Fair Value models
Bear$11.82Fair Value $17.91Bull$22.39
Price $20.35 · Downside -12.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$13.91$21.07$26.3452
All 1 models by family
Asset-Based
NCAV (Graham)$13.91$21.07$26.3452
The fair value above starts from this blend and is adjusted for dilution from new shares.
AI conclusion: The business shows promise through sustained weight loss data from its oral GLP-1 candidate yet faces heavy cash burn with no commercial revenue or traction.
Main risk: The extended phase 3 timeline until 2028 risks prolonging cash burn and delaying any revenue in a field already dominated by injectable therapies from larger players.
Structure Therapeutics continues to report sustained weight loss with its oral GLP-1 candidate in long-term extension data, without signs of plateauing. This comes as the company pushes forward with phase 3 trials that will not read out until 2028, in a field crowded by injectable therapies from bigger players. Does the potential for an oral option outweigh the risks of that extended timeline or not?
Compare Structure Therapeutics Inc. American Depositary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−12.0% · Above median
Profitability
Return on assets−8.9% · Above median
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Structure Therapeutics Inc. American Depositary Shares Fair Value". https://www.fairvalue-calculator.com/stock/GPCR
Frequently asked questions
Is Structure Therapeutics Inc. (GPCR) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $17.91 versus a price of $20.35, about 12% lower (overvalued).
What is the fair value of GPCR?
Our model-based fair value for Structure Therapeutics Inc. is $17.91 (as of Nov 6, 2026), built from audited fundamentals. The current price: $20.35.
What is the quality score of GPCR?
Structure Therapeutics Inc. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Structure Therapeutics Inc. (GPCR)?
Our model-based price target is the fair value of $17.91 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $11.82, optimistic scenario $22.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Structure Therapeutics Inc. American Depositary Shares stock forecast for 2026?
Our models put fair value at $17.91, about 12% lower versus a price of $20.35 (overvalued). Cautious scenario $11.82, optimistic scenario $22.39. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Structure Therapeutics Inc. (GPCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Structure Therapeutics Inc. it is $17.91 per share (as of Nov 6, 2026), against a price of $20.35. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Structure Therapeutics Inc. American Depositary Shares stock overvalued or undervalued in 2026?
As of Nov 6, 2026, GPCR trades above its calculated fair value: price $20.35, fair value $17.91, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GPCR?
No. The price is what the market pays today ($20.35); the fair value is what the company's own numbers justify ($17.91). For Structure Therapeutics Inc. the two are $2.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Structure Therapeutics Inc. American Depositary Shares worth?
The market values Structure Therapeutics Inc. at about $1.5B (market capitalisation, as of Nov 6, 2026). Per share that is $20.35; our models calculate a fair value of $17.91 per share.
What do the bullish and bearish scenarios say about GPCR?
Our models span a range for Structure Therapeutics Inc.: cautious scenario $11.82, base $17.91, optimistic $22.39 per share (as of Nov 6, 2026, price $20.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Structure Therapeutics Inc. (GPCR)?
Balance-sheet figures for Structure Therapeutics Inc. (as of Nov 6, 2026): return on equity −20.2%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is GPCR from its 52-week high?
Structure Therapeutics Inc. trades at $20.35, about 78% below its 52-week high of $93.79 and 7% above the low of $19.08 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $17.91 is for.
Which stocks are comparable to Structure Therapeutics Inc. American Depositary Shares?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Structure Therapeutics Inc. American Depositary Shares stock attractive at the current price?
The data as of Nov 6, 2026: price $20.35, calculated fair value $17.91 (−12%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GPCR calculated?
We run Structure Therapeutics Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $17.91 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Structure Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Structure Therapeutics Inc. (GPCR)?
The closing price on Nov 6, 2026 was $20.35. Our model-based fair value is $17.91, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Structure Therapeutics Inc. American Depositary Shares right now?
A fairly wide model range ($11.82 to $22.39) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Structure Therapeutics Inc.
How large is the market capitalisation of Structure Therapeutics Inc. (GPCR)?
The market capitalisation of Structure Therapeutics Inc. is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Structure Therapeutics Inc. (GPCR)?
Earnings per share at Structure Therapeutics Inc. are $−3.03. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Structure Therapeutics Inc. (GPCR)?
The return on equity (ROE) of Structure Therapeutics Inc. is −20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Structure Therapeutics Inc. (GPCR)?
On an EBIT basis the return on assets of Structure Therapeutics Inc. is −28.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Structure Therapeutics Inc. (GPCR) generate?
The free cash flow of Structure Therapeutics Inc. is −$226M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Structure Therapeutics Inc. (GPCR) hold?
Structure Therapeutics Inc. holds more cash than debt, $793M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Structure Therapeutics Inc. American Depositary Shares in the live analysis
One click puts Structure Therapeutics Inc. American Depositary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
